AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25711836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan 50 mg twice daily for 90 days
Number of subjects: 75
Study 25711836 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study 23669880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle training (8 weeks of increasing intensity stationary cycle training)
Number of subjects: 18
Study 23669880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle training
Number of subjects: 18
Study 20063429 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline uric acid levels
Number of subjects: 347
Study 18718966 — intervention group
Group type: EXPERIMENTAL
Intervention: Orexin A intranasally
Number of subjects: 10
Study 18718966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16847549 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.82 g/kg dose of alcohol
Number of subjects: 54
Study 16847549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 12742478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus, cyclosporine microemulsion formulation, and prednisone
Number of subjects: 81
Study 12742478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-based protocol with decreased calcineurin inhibitors
Number of subjects: 81
Study 10803800 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 100 mg three times daily
Number of subjects: 59
Study 10803800 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 200 mg three times daily
Number of subjects: 59
Study 10803800 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 59
Study 10803800 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone
Number of subjects: 59
Study 10803800 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone withdrawal
Number of subjects: 59
Study 9107558 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphytose (EUP) - two tablets three times a day over 28 days
Number of subjects: 182
Study 9107558 — intervention group
Group type: COMPARATOR
Intervention: Placebo - two tablets three times a day over 28 days
Number of subjects: 182
Study 1547052 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive therapeutic suggestions (tapes)
Number of subjects: 75
Study 1547052 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified history of the Queen's Medical Centre (tapes)
Number of subjects: 75
Study 1547052 — intervention group
Group type: COMPARATOR
Intervention: No message (control group)
Number of subjects: 75
Study 2865746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 299
Study 2865746 — intervention group
Group type: COMPARATOR
Intervention: 20 mg temazepam
Number of subjects: 299
Study 30314747 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert observation of hand hygiene compliance
Number of subjects: 0
Study 30314747 — intervention group
Group type: COMPARATOR
Intervention: Standard methods of hand hygiene compliance monitoring
Number of subjects: 0
Study 30463831 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl carprost suppository combined with oxytocin
Number of subjects: 180
Study 30463831 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (control group)
Number of subjects: 180
Study 27248440 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (10 mg enalapril)
Number of subjects: 80
Study 27248440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25148302 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired sets with minimal allowable rest (PMR)
Number of subjects: 15
Study 25148302 — intervention group
Group type: EXPERIMENTAL
Intervention: P30 - 30-second rest between paired sets
Number of subjects: 15
Study 25148302 — intervention group
Group type: EXPERIMENTAL
Intervention: P1 - 1-minute rest between paired sets
Number of subjects: 15
Study 22767495 — intervention group
Group type: EXPERIMENTAL
Intervention: dance-based exergaming
Number of subjects: 40
Study 22767495 — intervention group
Group type: COMPARATOR
Intervention: wait-list control
Number of subjects: 40
Study 20002624 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietary and lifestyle counselling
Number of subjects: 1062
Study 20002624 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1062
Study 18698545 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg)
Number of subjects: 78
Study 18698545 — intervention group
Group type: COMPARATOR
Intervention: Control (no statin)
Number of subjects: 78
Study 15597181 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeded manual choice reaction time (RT) task
Number of subjects: 0
Study 15597181 — intervention group
Group type: COMPARATOR
Intervention: Cued visual target report from a masked display
Number of subjects: 0
Study 15597181 — intervention group
Group type: EXPERIMENTAL
Intervention: Task order manipulation (reversed order of tasks)
Number of subjects: 0
Study 15597181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued location of the target
Number of subjects: 0
Study 15597181 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of target features to be reported
Number of subjects: 0
Study 14660913 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin/dexamethasone
Number of subjects: 201
Study 14660913 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin alone
Number of subjects: 201
Study 10227630 — intervention group
Group type: COMPARATOR
Intervention: 25 microg/kg BDNF for 9 months
Number of subjects: 1135
Study 10227630 — intervention group
Group type: COMPARATOR
Intervention: 100 microg/kg BDNF for 9 months
Number of subjects: 1135
Study 10227630 — intervention group
Group type: COMPARATOR
Intervention: 100 microg/kg BDNF for 9 months (BDNF 'responders')
Number of subjects: 1135
Study 10227630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1135
Study 8063466 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) group, 2 grams L-carnitine in a citrus drink twice daily for 7 days
Number of subjects: 20
Study 8063466 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) group, citrus drink only for 7 days
Number of subjects: 20
Study 2522729 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 to 8 mg/day)
Number of subjects: 16
Study 2522729 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg/day)
Number of subjects: 16
Study 2522729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 5072236 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 1 task difficulty (light signals only)
Number of subjects: 15
Study 5072236 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 2 task difficulty (light signals with driving simulator film)
Number of subjects: 15
Study 5072236 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 3 task difficulty (conflicting light signals with driving simulator film)
Number of subjects: 15
Study 5072236 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate across task levels
Number of subjects: 15
Study 30895824 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuzijue Qigong (LQG) training method with 6 monosyllabic speech sounds
Number of subjects: 48
Study 30895824 — intervention group
Group type: COMPARATOR
Intervention: Conventional voice training (abdominal breathing and yawn‐sign exercises)
Number of subjects: 48
Study 28321881 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier load (HL; 80% MVIT)
Number of subjects: 8
Study 28321881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter load (LL; 30% MVIT)
Number of subjects: 8
Study 28321881 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced repetition (FR)
Number of subjects: 8
Study 28321881 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakdown set (BD)
Number of subjects: 8
Study 24373610 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81mg/day) for 7 days
Number of subjects: 30
Study 24373610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) (4g/day) for 28 days
Number of subjects: 30
Study 24373610 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Aspirin and Fish Oil for 7 days
Number of subjects: 30
Study 22435509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Number of subjects: 169
Study 22435509 — intervention group
Group type: COMPARATOR
Intervention: Concomitant therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Number of subjects: 169
Study 22435509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 169
Study 22435509 — intervention group
Group type: COMPARATOR
Intervention: Concomitant therapy
Number of subjects: 169
Study 19912138 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care
Number of subjects: 137
Study 19912138 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 137
Study 18686631 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 41
Study 18686631 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 41
Study 16118546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 63
Study 16118546 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin plus eptifibatide
Number of subjects: 63
Study 14519753 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 3385
Study 10754950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% benzalkonium chloride vaginal suppository and neonatal bath
Number of subjects: 108
Study 10754950 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal suppository and neonatal bath
Number of subjects: 108
Study 10754950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% benzalkonium chloride
Number of subjects: 108
Study 10754950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 8965890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg, two-hour intravenous infusion monthly for 12 cycles)
Number of subjects: 380
Study 8965890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 1582586 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of ethanolamine oleate and thrombin
Number of subjects: 38
Study 1582586 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 38
Study 1582586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 4051527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen application (various brands)
Number of subjects: 50
Study 4051527 — intervention group
Group type: EXPERIMENTAL
Intervention: Two specific sunscreens
Number of subjects: 50
Study 31537221 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-pyloric feeding
Number of subjects: 175
Study 31537221 — intervention group
Group type: COMPARATOR
Intervention: Gastric feeding
Number of subjects: 175
Study 31537221 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscope treatment
Number of subjects: 175
Study 30064517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) bolus of tranexamic acid (TXA) peri-operatively plus oral TXA post-operatively for 24 hours
Number of subjects: 1166
Study 30064517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) bolus of TXA peri-operatively
Number of subjects: 1166
Study 30064517 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no TXA)
Number of subjects: 1166
Study 26329313 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-ketamine combination (GroupPK, n: 48)
Number of subjects: 95
Study 26329313 — intervention group
Group type: COMPARATOR
Intervention: Propofol (GroupP, n: 47)
Number of subjects: 95
Study 24569158 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted hypertension self-management interventions
Number of subjects: 0
Study 24569158 — intervention group
Group type: COMPARATOR
Intervention: Established hypertension self-management interventions
Number of subjects: 0
Study 22759721 — intervention group
Group type: EXPERIMENTAL
Intervention: Any NSAID
Number of subjects: 4735
Study 22759721 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4735
Study 22759721 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAIDs
Number of subjects: 4735
Study 22759721 — intervention group
Group type: EXPERIMENTAL
Intervention: Any NSAID (among men with no indications for NSAID use)
Number of subjects: 4735
Study 22759721 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis
Number of subjects: 4735
Study 22759721 — intervention group
Group type: EXPERIMENTAL
Intervention: Other inflammation-related musculoskeletal conditions
Number of subjects: 4735
Study 22759721 — intervention group
Group type: EXPERIMENTAL
Intervention: Headaches
Number of subjects: 4735
Study 19535988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg kg(‐1) ketamine followed by a continuous infusion of 1.4 microg kg(‐1) min(‐1) over 24 h
Number of subjects: 37
Study 19535988 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 37
Study 19535988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg kg(‐1) ketamine
Number of subjects: 37
Study 17591127 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane sedation via AnaConDa
Number of subjects: 20
Study 17591127 — intervention group
Group type: COMPARATOR
Intervention: Midazolam sedation (intravenous)
Number of subjects: 20
Study 17591127 — intervention group
Group type: EXPERIMENTAL
Intervention: End‐tidal isoflurane concentration
Number of subjects: 20
Study 17591127 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS XP
Number of subjects: 20
Study 16327136 — intervention group
Group type: EXPERIMENTAL
Intervention: Music distraction
Number of subjects: 40
Study 16327136 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 11888869 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion lymph node dissection (CLND)
Number of subjects: 274
Study 11888869 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive SLNs detected by immunohistochemistry (IHC)
Number of subjects: 274
Study 11888869 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive SLNs detected by hematoxylin and eosin (H&E) staining
Number of subjects: 274
Study 10343981 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents (cyclosporin A and methotrexate)
Number of subjects: 0
Study 10343981 — intervention group
Group type: EXPERIMENTAL
Intervention: Choleretic agents (ursodeoxycholic acid)
Number of subjects: 0
Study 10343981 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary tract reconstructive surgery
Number of subjects: 0
Study 10343981 — intervention group
Group type: COMPARATOR
Intervention: Proctocolectomy for CUC
Number of subjects: 0
Study 10343981 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotopic liver transplantation
Number of subjects: 0
Study 10343981 — intervention group
Group type: COMPARATOR
Intervention: Cupruretic agents
Number of subjects: 0
Study 7769297 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms of rHA0
Number of subjects: 127
Study 7769297 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms of rHA0 plus alum
Number of subjects: 127
Study 7769297 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 micrograms of rHA0
Number of subjects: 127
Study 7769297 — intervention group
Group type: EXPERIMENTAL
Intervention: Licensed subvirion vaccine
Number of subjects: 127
Study 7769297 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 127
Study 1707337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cronassial (100 mg) administered by intramuscular (IM) injection daily
Number of subjects: 27
Study 1707337 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (2.0 mg/m2 every other week by bolus injection followed by a 3-day continuous IV infusion)
Number of subjects: 27
Study 1707337 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (50 mg/d for 3 days weekly or every other week)
Number of subjects: 27
Study 1707337 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic studies of peripheral nerve function
Number of subjects: 27
Study 6805176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ml polycomponent meningococcal vaccine
Number of subjects: 168
Study 6805176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml polycomponent meningococcal vaccine
Number of subjects: 168
Study 6805176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml polycomponent meningococcal vaccine
Number of subjects: 168
Study 6805176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 ml physiological saline)
Number of subjects: 168
Study 30951604 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered physical therapy prehabilitation program
Number of subjects: 118
Study 30951604 — intervention group
Group type: COMPARATOR
Intervention: Conventional preoperative care
Number of subjects: 118
Study 28939648 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise (40% peak power output)
Number of subjects: 22
Study 28939648 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity interval exercise (70% peak power output)
Number of subjects: 22
Study 28939648 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 22
Study 26946925 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated catheters
Number of subjects: 1485
Study 26946925 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-impregnated catheters
Number of subjects: 1485
Study 26946925 — intervention group
Group type: COMPARATOR
Intervention: Standard central venous catheters
Number of subjects: 1485
Study 25201152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 22
Study 25201152 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study 22855633 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever-range whole-body hyperthermia (FR-WBH)
Number of subjects: 18
Study 22855633 — intervention group
Group type: COMPARATOR
Intervention: Control (propofol sedation only)
Number of subjects: 18
Study 21037443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 178
Study 17890500 — intervention group
Group type: EXPERIMENTAL
Intervention: Large amount of food
Number of subjects: 28
Study 17890500 — intervention group
Group type: COMPARATOR
Intervention: Small amount of food
Number of subjects: 28
Study 16282291 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg/day)
Number of subjects: 276
Study 16282291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 12113567 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (Sl‐‐30NB)
Number of subjects: 80
Study 12113567 — intervention group
Group type: COMPARATOR
Intervention: Acrylic intraocular lens (Acrysof MA60BM)
Number of subjects: 80
Study 12113567 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (Sl‐‐30NB) with concurrent ocular diseases
Number of subjects: 80
Study 12113567 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (Sl‐‐30NB) without concurrent ocular diseases
Number of subjects: 80
Study 12113567 — intervention group
Group type: COMPARATOR
Intervention: Acrylic intraocular lens (Acrysof MA60BM) with concurrent ocular diseases
Number of subjects: 80
Study 12113567 — intervention group
Group type: COMPARATOR
Intervention: Acrylic intraocular lens (Acrysof MA60BM) without concurrent ocular diseases
Number of subjects: 80
Study 10203311 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulation (repeating a number aloud)
Number of subjects: 36
Study 10203311 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting backwards aloud in multiples of seven (articulation and attention)
Number of subjects: 36
Study 10203311 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting backwards silently (attention)
Number of subjects: 36
Study 10203311 — intervention group
Group type: COMPARATOR
Intervention: No mental task (neither articulation nor attention)
Number of subjects: 36
Study 8525537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir (6 mg/kg once a day, Monday through Friday) for 4 or more weeks
Number of subjects: 51
Study 8525537 — intervention group
Group type: COMPARATOR
Intervention: Less than 2 weeks of ganciclovir
Number of subjects: 51
Study 8525537 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 or more weeks of ganciclovir
Number of subjects: 51
Study 2239781 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% CHO diet
Number of subjects: 0
Study 2239781 — intervention group
Group type: COMPARATOR
Intervention: 43% CHO diet
Number of subjects: 0
Study 367238 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase admixed with local anesthetic
Number of subjects: 2
Study 367238 — intervention group
Group type: COMPARATOR
Intervention: No hyaluronidase
Number of subjects: 2
Study 31185030 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time portable nanopore sequencing of virus isolates from clinical samples
Number of subjects: 11
Study 31185030 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis combined with CHIKV notified case numbers
Number of subjects: 11
Study 28859326 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA-light (prednisolone and MTX)
Number of subjects: 162
Study 28859326 — intervention group
Group type: COMPARATOR
Intervention: COBRA therapy (prednisolone, MTX and SSZ)
Number of subjects: 162
Study 28859326 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA-light and COBRA therapy
Number of subjects: 162
Study 25588594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine plus 0.5 µg.kg‐1 dexmedetomidine (group LD1)
Number of subjects: 90
Study 25588594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine plus 1 µg.kg‐1 dexmedetomidine (group LD2)
Number of subjects: 90
Study 25588594 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar ropivacaine (group L)
Number of subjects: 90
Study 23236956 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A + mCIMT
Number of subjects: 34
Study 23236956 — intervention group
Group type: COMPARATOR
Intervention: BoNT‐A + BOT
Number of subjects: 34